274 related articles for article (PubMed ID: 19216579)
1. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
Baillie TA
Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
[TBL] [Abstract][Full Text] [Related]
2. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
[TBL] [Abstract][Full Text] [Related]
3. An accurate-mass-based spectral-averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC-MS data.
Zhu P; Tong W; Alton K; Chowdhury S
Anal Chem; 2009 Jul; 81(14):5910-7. PubMed ID: 19518135
[TBL] [Abstract][Full Text] [Related]
4. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
[TBL] [Abstract][Full Text] [Related]
5. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
[TBL] [Abstract][Full Text] [Related]
6. Predicting circulating human metabolites: how good are we?
Anderson S; Luffer-Atlas D; Knadler MP
Chem Res Toxicol; 2009 Feb; 22(2):243-56. PubMed ID: 19138063
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of parent drug and its unstable metabolites by in situ coulometric oxidation and liquid chromatography-tandem mass spectrometry.
Tong W; Chowdhury SK; Su AD; Alton KB
Anal Chem; 2010 Dec; 82(24):10251-7. PubMed ID: 21105697
[TBL] [Abstract][Full Text] [Related]
8. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
Zhu M; Zhang D; Zhang H; Shyu WC
Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
[TBL] [Abstract][Full Text] [Related]
9. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
10. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
[TBL] [Abstract][Full Text] [Related]
11. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
Nassar AE; Talaat RE; Kamel AM
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
[TBL] [Abstract][Full Text] [Related]
12. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
Espina R; Yu L; Wang J; Tong Z; Vashishtha S; Talaat R; Scatina J; Mutlib A
Chem Res Toxicol; 2009 Feb; 22(2):299-310. PubMed ID: 18980340
[TBL] [Abstract][Full Text] [Related]
13. A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices.
Zhu P; Ding W; Tong W; Ghosal A; Alton K; Chowdhury S
Rapid Commun Mass Spectrom; 2009 Jun; 23(11):1563-72. PubMed ID: 19408276
[TBL] [Abstract][Full Text] [Related]
14. Screening for pharmaco-toxicologically relevant compounds in biosamples using high-resolution mass spectrometry: a 'metabolomic' approach to the discrimination between isomers.
Liotta E; Gottardo R; Bertaso A; Polettini A
J Mass Spectrom; 2010 Mar; 45(3):261-71. PubMed ID: 20014151
[TBL] [Abstract][Full Text] [Related]
15. Metabolites and safety: What are the concerns, and how should we address them?
Smith DA; Obach RS
Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
[TBL] [Abstract][Full Text] [Related]
16. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
17. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
Smith DA; Obach RS
Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
[TBL] [Abstract][Full Text] [Related]
18. Strategy for genotoxicity testing--metabolic considerations.
Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
[TBL] [Abstract][Full Text] [Related]
19. Interpretation and considerations on the safety evaluation of human drug metabolites.
Atrakchi AH
Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
[TBL] [Abstract][Full Text] [Related]
20. Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates.
Fernández-Metzler CL; Owens KG; Baillie TA; King RC
Drug Metab Dispos; 1999 Jan; 27(1):32-40. PubMed ID: 10068285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
